10 Analysts Have This to Say About Karuna Therapeutics
Portfolio Pulse from Benzinga Insights
10 analysts have provided ratings for Karuna Therapeutics (NASDAQ:KRTX) in the last quarter, with 3 being bullish, 6 somewhat bullish, and 1 indifferent. The average price target is $266.0, compared to the current price of $174.61, implying an upside. The average has increased by 0.09% from the previous average price target of $265.75.
August 22, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts are generally bullish on Karuna Therapeutics with an average price target of $266.0, indicating potential upside from the current price.
The majority of analysts are bullish or somewhat bullish on Karuna Therapeutics, indicating a positive sentiment towards the stock. The average price target is significantly higher than the current price, suggesting potential for price appreciation. This could have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100